Xi’an Maidefa Pharmaceutical

Xi'an Maidefa Pharmaceutical is a clinical-stage biotechnology company based in Xi'an, China, specializing in the development of innovative peptide therapeutics for metabolic diseases. The company's research focuses on multi-target agonists of the incretin system, aiming to provide superior treatments for obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Its lead asset, MDF-001, is a dual GLP-1 and GIP receptor agonist currently in Phase 2 clinical trials, demonstrating potential for significant weight loss and glycemic control. Maidefa utilizes a proprietary peptide engineering platform to optimize the stability and potency of its drug candidates. Backed by prominent investors like HighLight Capital, the company is positioned as a key player in the rapidly evolving metabolic health landscape in China and beyond.